Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Gefitinib in EGFR-mutant NSCLC
NCT02040064Phase 1Completed
- Sponsor
- Gustave Roussy
- Start
- Jan 2014
- Primary completion
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of tremelimumab in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Primary endpoint: Safety and tolerability of the association between Gefitinib and Tremelimumab at 42 days. Started Jan 2014; status: completed.
02
Drugs
tremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02040064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040064.